İntravitreal Deksametazon İmplantın Retinal Vasküler Hastalıklara Bağlı Maküla Ödeminde Etkinliği ve Güvenliği

Yıl 2025, Cilt: 22 Sayı: 4, 775 - 781, 25.12.2025

Eyüp Özcan , Erol Coşkun

https://doi.org/10.35440/hutfd.1696127

Öz

Amaç: Diyabetik retinopati ve retinal ven tıkanıklığı en sık görülen retinal vasküler hastalıklardır. Bu çalışmada retinal vasküler hastalıklara bağlı makula ödemi üzerine tek doz intravitreal deksametazon implant enjeksiyonunun etkinliği ve güvenliği araştırılmıştır.
Materyal ve metod: Retinal vasküler hastalıklara bağlı makula ödemi olan ve en az 6 ay takip edilen 30 (13 retinal ven dal tıkanıklığı-BRVO, 7 santral retinal ven tıkanıklığı-CRVO ve 10 diyabetik makula ödemi-DME) hastanın tıbbi kayıtları retrospektif olarak değerlendirildi. En iyi düzeltilmiş görme keskinliği (BCVA), santral makula kalınlığı (CMT), göz içi basıncı (GİB) ve katarakt ilerlemesi birinci hafta, 1., 2., 3. ve 6. aylarda ölçüldü.
Bulgular: Gruplar demografik özellikler açısından benzerdi (p>0,05). BRVO’da, tüm vizitlerde BCVA’da başlangıç değerine göre istatistiksel olarak anlamLı bir iyileşme görülmedi (p>0,05). Başlangıç değerine göre 1., 2. ve 3. aylarda CMT azalmasında istatistiksel olarak anlamLı fark vardı (p<0,05). CRVO’da, 1. ve 2.aylarda BCVA'da istatistiksel olarak anlamLı iyileşme gözlendi(p<0,05). Başlangıç değerine göre CMT azalmaları, CRVOgrubunda tüm vizitlerde istatistiksel olarak anlamLı farklılıkgösterdi (p<0,05). DME grubunda, BCVA, 2. ve 3. aylarda başlangıçdeğerine göre anlamLı şekilde daha yüksekti (p<0,05) ve 1., 2.,3.ve 6. aylardaki CMT azalmaları istatistiksel olarak anlamLıydı(p<0,05). Ortalama GİB değerleri, tüm hastalarda 1. ve 2. aylardaanlamLı şekilde daha yüksekti. GİB artışları geçiciydi ve topikalantiglokomatöz ilaçlarla tedavi edildi. Fakik çalışma gözlerinde 6aylık katarakt insidansı %17 idi ve 6. ayda opere edildi.
Sonuç: Deksametazon implantının intravitreal enjeksiyonu etkilive güvenli bir yöntemdir ve retinal ven tıkanıklıkları ve DMEnedeniyle makula ödemi olan hastalarda BCVA’da artma, CMT’deazalma sağlar. 6. ayın sonunda geçici GİB artışı ve kataraktilerlemesi beklenen yan etkilerdir.

Anahtar Kelimeler

Deksametazon intravitreal implant , Retinal ven tıkanıklığı , Diyabetik retinopati , Maküla ödemi

Safety and Efficacy of Intravitreal Dexamethasone Implant on Macular Edema Due to Retinal Vascular Diseases

Öz

Background: Diabetic retinopathy and retinal vein occlusion are the most common retinal vascular diseases. This study investigates the efficacy and safety of a single dose intravitreal dexamethasone implant injection on macular edema due to retinal vascular diseases.
Materials and Methods: The medical records of 30 (13 with branch retinal vein occlusion-BRVO, 7 with central retinal vein occlusion-CRVO and 10 with diabetic macular edema-DME) patients with macular edema secondary to retinal vascular diseases and at least 6 months follow-up, were evaluated retrospectively. Best corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP) and cataract progression were performed at first week, 1st, 2nd, 3rd and 6th months.
Results: The groups were similar in terms of demographic characteristics (p>0,05). In BRVO, there were no statistically significant improvement in BCVA from baseline at all visits (p>0.05). There were statistically significant difference at CMT reduction at 1st, 2nd and 3rd months from baseline (p<0.05). In CRVO, statistically significant improvement in BCVA was observed at 1st and 2nd months (p<0.05). CMT reductions from baseline were statistically significant different at all visits in CRVO group (p<0.05). In DME group, BCVA was significantly higher at 2nd and 3rd months from baseline (p<0.05) and CMT reductions at 1st, 2nd, 3rd and 6th months were statistically significant (p<0.05). The mean IOP values were significantly higher at 1st and 2nd months in all patients. IOP increases were transient and treated with topical antiglaucomatous medicine. The 6-month incidence of cataract in phakic study eyes was 17% and cataracts were extracted at 6th month.
Conclusion: Intravitreal injection of dexamethasone implant is an effective and safe method and provides increased BCVA, decreased CMT in patients with macular edema due to retinal vein occlusions and DME. Transient IOP increase and cataract progression at the end of 6th month are expected side effects.

Anahtar Kelimeler

Dexamethasone intravitreal implant , Retinal vein occlusion , Diabetic retinopathy , Macular edema

Etik Beyan

This study was approved by the Gaziantep University Clinical Research Ethics Committee (approval no: 24.03.2014/130, date: March 24, 2014).

Destekleyen Kurum

none

Kaynakça

• 1. McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010; 117 (6): 1113-23.
• 2. Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: new consepts in patho-physiology and treatment. Cell Biosci 2014; (4): 27.
• 3. Sarao V, Veritti D, Boscia F, Lanzetta P. Intravitreal Steroids for the Treatment of Retinal Diseases. Scientific World Journal 2014; (8);2014.
• 4. Malclès A, Dot C, Voirin N, Vié AL, Agard E, Bellocq D. Safety of intravitreal dexamethasone implant (OZURDEX): the SAFODEX study. Incidence and risk factors of ocular hypertension. Retina 2017;37(7):1352-9.
• 5. Whitcup SM, Robinson MR. Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis. Ann N Y Acad Sci 2015; 1358:1-12.
• 6. Garweg JG, Zandi S. Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment. Graefes Arch Clin Exp Ophthalmol 2016;254(7):1257-65.
• 7. Hahn P, Fekrat S. Best practices for treatment of retinal vein occlusion. Curr Opin Ophthalmol 2012;23(3):175-81.
• 8. Imai S, Otsuka T, Naito A, Shimazawa M, Hara H. Triamcinolone Acetonide Suppresses Inflammation and Facilitates Vascular Barrier Function in Human Retinal Microvascular Endothelial Cells. Current Neurovascular Research 2017;14(3):232-41.
• 9. Ip MS,Scott IU, Vanveldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127 (9): 1101-14.
• 10. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, et al. Pharmacokinetics and pharmacodynamics of the sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011; 52(1):80-6.
• 11. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Randonmized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular edema Due to Retinal Vein Occlusion. Ophthalmology 2010;117(6):1134-46.
• 12. Lazic R, Lukic M, Boras I, Draca N, Vlasic M, Gabric N, et al. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina 2014; 34(4):719-24.
• 13. Pacella E, Rita Vestri A, Muscella R, Rosaria Carbotti M, Castelluci M, Coi L, et al. Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema. Clin Ophthalmol 2013; 7(7): 1423-8.
• 14. Zucchiatti I, Lattanzio R, Querques G, Querques L, Del Turco C, Cascavilla ML, et al. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica 2012; 228(2): 117-22.
• 15. Castro-Navarro V, Cervera-Taulet E , Navarro-Palop C , Monferrer-Adsuara C, Hernández-Bel L, Montero-Hernández J. Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema. BMC Opthalmol 2019;19(1):15.
• 16. Yorgun MA, Toklu Y, Mutlu M, Uysal BS, Çakmak HB. Efficacy of single-dose dexamethasone implantation in patients with persistent diabetic macular edema. Int Ophthalmol 2016 ;36(4):531-9.
• 17. Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al. A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema: The BEVORDEX Study. Ophthalmology 2014; 121: 2473-81.
• 18. Tang HX, Li JJ, Yuan Y, Ling Y, Mei Z, Zou H. Comparing the efficacy of dexamethasone implant and anti-VEGF for the treatment of macular edema: A systematic review and meta-analysis. PLoS One 2024 ;19(7):e0305573.
• 19. Kuppermann BD, Haller JA, Bandello F, Loewenstein A, Jiao J, Li, et al. Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. Retina 2014; 34(12): 1743-9.
• 20. Yap TE, Husein S, Ollero JAMI, Colizzi B, Cordeiro MF, Younis S. The efficacy of dexamethasone implants following anti-VEGF failure for macular oedema in retinal vein occlusion Eur J Ophthalmol 2021;31(6):3214-22.
• 21. Neves P, Ornelas M, Matias I, Rodrigues J, Santos M, Medeiros MD, Martins D. Dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema: real-world data versus clinical trials outcomes. J Ophthalmol 2021 Oct 18;14(10):1571-80.
• 22. Carnevali A, Bacherini D, Metrangolo C, Chiosi F Viggiano P, Astarita C, et al. Long term efficacy and safety profile of dexamethasone intravitreal implant in retinal vein occlusions: a systematic review. Front Med (Lausanne) 2024; 29:11:1454591.
• 23. Mayer WJ, Wolf A, Kernt M, Kook D, Kampik A, Ulbig M, et al. Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye 2013; 27(7):816-22.